MedTrace Logo

[KJ-INT-002] BE Study

NCT03509831 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2018-04-26

No results posted yet for this study

Summary

Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 after Oral Administration to Healthy Adult Male Subjects

Conditions

  • Gastritis

Interventions

DRUG

INT-2150

1. Period: INT-2150 2. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg

DRUG

Irsogladine maleate 2 mg+Nizatidine 150 mg

1. Period: Irsogladine maleate 2 mg+Nizatidine 150 mg 2. Period: INT-2150

Sponsors & Collaborators

  • Kukje Pharma

    lead OTHER

Principal Investigators

  • Sang-Heon Cho · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-02
Primary Completion
2018-01-24
Completion
2018-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509831 on ClinicalTrials.gov